Implantation of C6 astrocytoma spheroid into collagen type I gels: invasive, proliferative, and enzymatic characterizations.
A three-dimensional model has been developed in which C6 astrocytoma spheroids of defined sizes are embedded into collagen type I gels. The authors have monitored cell invasive behavior; obtained quantitative data on cell invasion, proliferation, and enzymatic activity; assessed cell-cell interactions by altering the spheroid size used; and studied cell-matrix interactions by modifying the matrix components. Their results show that C6 astrocytoma cells detach from the spheroid surface and invade the gel as single cells by means of a system that appears to be dependent on metalloprotease function. These invasive cells have a low proliferative index. Larger spheroids with central hypoxic microregions possess cells that invade the gel at faster rates; this could be correlated with the release of increased collagen type I degrading activity. Extracellular matrix proteins, such as laminin, fibronectin, and collagen type IV have no significant influence on invasive activity, whereas hyaluronic acid decreases and human central nervous system myelin increases invasion. New strategies directed at the treatment of malignant gliomas must take into account the subpopulation of malignant cells located long distances from the major tumor mass. The spheroid invasion model may provide specific insights into the behavior of these invasive cells.
Tamaki
M
M
Division of Neurosurgery, London Health Sciences Centre, University of Western Ontario, Canada.
McDonald
W
W
Amberger
V R
VR
Moore
E
E
Del Maestro
R F
RF
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D001254:Astrocytoma / Q000201:enzymology / Q000473:pathology*; D002448:Cell Adhesion; D002450:Cell Communication; D002455:Cell Division; D015687:Cell Hypoxia; D048429:Cell Size; D003094:Collagen / Q000378:metabolism / Q000494:pharmacology; D003470:Culture Media; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D005109:Extracellular Matrix / Q000737:chemistry; D005353:Fibronectins / Q000494:pharmacology; D005782:Gels; D005910:Glioma / Q000473:pathology / Q000628:therapy; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000502:physiology; D009185:Myelin Proteins / Q000494:pharmacology; D009361:Neoplasm Invasiveness; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D011480:Protease Inhibitors / Q000494:pharmacology; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D018874:Spheroids, Cellular / Q000201:enzymology / Q000473:pathology*; D014407:Tumor Cells, Cultured
D003470:Culture Media; D015853:Cysteine Proteinase Inhibitors; D005353:Fibronectins; D005782:Gels; D007797:Laminin; D009185:Myelin Proteins; D011480:Protease Inhibitors; D015842:Serine Proteinase Inhibitors; D006820:Hyaluronic Acid; D003094:Collagen; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases